WALTHAM, Mass.--(BUSINESS WIRE)--June 29, 2005--Pyxis Mobile, Inc., a leading provider of innovative wireless software that promotes asset growth for the investment industry, has been named to the ...

BOSTON--(BUSINESS WIRE)--Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor ...

Originally introduced as “the next generation customizable cinema camera” for all types of filmmakers and video professionals, the original PYXIS 6K model quickly established itself as a top option ...

Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results for the ADC last month. The Boston biotech is ...

Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO ...

Pyxis Oncology Inc., a company building a portfolio of antibody-drug conjugates (ADCs) and immunotherapies for cancer, has closed a $152 million series B financing co-led by Arix Bioscience and RTW ...